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Abstract The IKVAV sequence, one of the most potent active 
sites of laminin-1, has been shown to promote cell adhesion, 
neurite outgrowth, and tumor growth. Here we have determined 
the structural requirements of the IKVAV sequence for cell at- 
tachment and neurite outgrowth using various 12-mer synthetic 
peptide analogs. All-L- and alI-D-IKVAV peptides showed cell 
attachment and neurite outgrowth activities. In contrast, all-L- 
and all-D-reverse-sequence peptides were not active. Some of the 
analogs, in which the lysine and isolencine residues of the IKVAV 
peptide were substituted with different amino acids, promoted cell 
attachment, but none of the analog peptides showed neurite out- 
growth activity comparable to that of the IKVAV peptide. These 
results suggest hat the lysine and isoleucine residues are critical 
for the biological functions of the IKVAV peptide. 
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1. Introduction 
Laminins comprise a family of large heterotrimeric basement 
membrane glycoproteins, which have diverse biological activi- 
ties including promoting cell adhesion, growth, migration, 
neurite outgrowth and differentiation, and influencing the 
metastatic potential of tumor cells [1-3]. Several laminin 
isoforms have been identified with at least eight genetically 
distinct chains [4]. Laminin-1 consists of three chains desig- 
nated al, fll and yl chains, and has a cruciform shape with one 
long and three short arms when examined by electron micros- 
copy [3,5]. Several active sequences of laminin-1 have been 
identified using synthetic peptide approaches [6-13]. An Ile- 
Lys-Val-Ala-Val (IKVAV) sequence located on the C-terminal 
end of the long arm of the laminin ~1 chain was found to be 
active in promoting cell adhesion, neurite outgrowth, angio- 
genesis, collagenase IV production, and tumor growth [10,14- 
17]. Cell surface IKVAV sequence binding proteins have been 
studied and a 110 kDa membrane-associated laminin-binding 
protein from brain was previously shown to bind to the IKVAV 
site [18]. Recently fl-amyloid precursor protein was found to 
specifically bind to the IKVAV peptide [19]. Additional 
IKVAV-specific binding proteins likely exist. 
It is important to identify the structural requirements of the 
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active IKVAV peptide for a better understanding its biological 
functions and specific interactions with its receptors or binding 
proteins. Previously, we showed the all-D-configuration seg- 
ment containing the IKVAV sequence of laminin ~1 chain had 
similar cell attachment and tumor growth activities to the all- 
L-peptide in vitro and in vivo [20]. These data suggested that 
the conformational status of the IKVAV domain is a contribut- 
ing factor in determining the biological activity but that there 
is no strict requirement for a specific chirality. Furthermore, 
such data suggested that there is a likely sequence specificity to 
the IKVAV region. 
In the present paper, we describe the structural requirements 
of IKVAV containing peptides of the laminin ~1 chain for cell 
adhesion and neurite outgrowth using various ynthetic peptide 
analogs. Peptide sequences from related laminin a chains con- 
taining the corresponding region were also evaluated. The data 
show cell attachment and neurite outgrowth activities have 
different structural requirements suggesting multiple cellular 
receptors. 
2. Materials and methods 
2.1. Synthesis of peptides and laminin-1 
All peptides were synthesized manually by 9-fluorenylmethyloxycar- 
bonyl (Fmoc) based solid-phase methods. The respective amino acids 
were condensed manually in a stepwise manner using the Tris-(alkoxy)- 
benzylamine r sin [21]. For condensation, diisopropylcarbodiimide-N- 
hydroxybenzotriazole wasemployed, and for deprotection of Fmoc 
groups, 20% piperidine in dimethylformamide wasemployed. The fol- 
lowing side chain protecting roups were used: Asn, trityl; Asp, Glu, 
and Ser, t-butyl; Arg, 2,2,5,7,8-pentamethylchroman-6-sulfonyl; Lys, 
t-bulyloxycarbonyl. The protected peptide resins were deprotected with 
a two-step rocedure, which consisted of consecutive treatments with 
trifluoroacetic acid (TFA)-thioanisole-m-cresol-ethanedithiol-H20 
(80: 5 : 5 : 5 : 5, by volume) at 20°C for 2 h followed by 1 M trimethylsilyl 
bromide-thioanisole in TFA in the presence of m-cresol and 
ethanedithiol at 4°C for 1 h [22]. Resulting crude peptides were purified 
by reverse-phase high performance liquid chromatography (HPLC) 
(using a Vydac 5C18 column with a gradient of H20/acetonitrile con- 
taining 0.1% TFA). Purity and identity of the synthetic peptides were 
confirmed by analytical reverse-phase HPLC and by amino acid analy- 
sis. Amino acid analyses were performed at the Faculty of Pharmaceu- 
tical Sciences, Kyoto University, Kyoto, Japan. 
Mouse laminin-1 was prepared from the Engelbreth-Holm-Swarm 
tumor as described previously [23]. 
2.2. Cells and culture 
PC12 cells were cultured in Dulbecco's modification ofEagle's me- 
dium (DMEM) containing 7.5% fetal bovine serum, 7.5% horse serum, 
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. 
These cells were generously provided by Gordon Guroff (NICHD, 
NIH). For the cell attachment and neurite outgrowth assays, the PC12 
cells were washed free of serum in 50% DMEM and 50% Ham's F12 
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(DMEM/F12) containing 2 mM glutamine, 100 U/ml penicillin, and 
100 mg/ml streptomycin. The cells were then cultured in the serum-free 
DMEM/F 12 for the duration of the attachment and neurite outgrowth 
assays. 
2.3. Cell attachment assay using synthetic peptides and laminin-1 
For attachment assays, the peptides were dissolved at a concentra- 
tion of 0.5 mg/ml in a 10% acetic acid solution. The indicated amounts 
of peptides were then added to the 16 mm diameter wells of a 24-well 
plate (Coming, Coming, NY). The peptides were then allowed to dry 
overnight. Next, a solution of 3% bovine serum albumin (BSA) was 
added to each well. After one hour, the BSA was removed and 50,000 
cells were added to each well in serum-free DMEM/F12. The cells were 
then incubated at 37°C in a CO2 incubator. After one hour, the medium 
and unattached cells were removed by aspiration and the attached cells 
were fixed and stained with Diff Qick (Baxter Scientific Products, 
Miami, FL). The percent of attached cells was determined by counting 
the center 2 mm 2 field in each of triplicate wells. The 2 mm 2 field 
represents 1.6% or 1164 of the well. Therefore the average number of 
cells in the 2 mm 2 field was divided by the total number of cells added 
to each well and this number was multiplied by 100 to determine the 
percent of cells attached. 
2.4. Neurite outgrowth assay 
For the neurite outgrowth assays, 16 mm diameter wells of a 24-well 
plate were coated with the indicated amounts of peptides as described 
above. After the peptides dried, the wells were rinsed with DMEM/F 12 
to remove residual acid. PC12 cells were primed with 100 ng/ml of nerve 
growth factor 24 h prior to their use. After priming, the PC 12 cells were 
washed free of serum and seeded into the wells in serum-free DMEM/ 
F12. The cells were then incubated at 37°C in a CO2 incubator for 24 h 
and the cells were fixed and stained as described above. In each of 
triplicate wells, a total of 100 cells was viewed and the percent which 
had neurites that extended twice the cell diameter or greater was deter- 
mined and averaged for each peptide amount ested. 
2.5. Coating eJficiency 
Coating efficiency of the synthetic peptides were determined as 
shown previously [20]. Laminin-1 (5/zg/well) and the synthetic peptides 
(500 mg/well) were each added to 6 wells of the 24-well dishes and dried 
at room temperature overnight. Half of peptide-coated wells were gen- 
tly washed three times with PBS (1 ml each). Coated peptides were twice 
extracted with PBS (1 ml each) containing 3% Triton X-100 and with 
PBS (1 ml). Fluorescamine in acetone (50/A, 1 mg/ml) was added to 
the extracted solutions (total 3 ml), and fluorescence emission at 475 
nm was determined using a Perkin-Elmer Model LS-5B Luminescence 
Spectrometer with excitation at 390 nm. Coating efficiencies (%) were 
determined using fluorescence intensity of PBS-washed samples relative 
to non-washed samples from the wells. 
3. Results and discussion 
Analog peptides were designed based on an IKVAV se- 
quence containing 12-mer peptide (LAM-L: mouse laminin c¢1 
chain residues 2097 2108 [24]) (Table 1). All-D-peptides con- 
taining IKVAV sequence (LAM-D) and all-L- and all-D- 
reverse-sequence p ptides (LAM-LR and LAM-DR,  respec- 
tively) were prepared. As a control, a peptide containing a 
randomized IKVAV region was also prepared. Lysine position 
substituted analogs, in which the lysine residue in the LAM-L  
peptide was replaced with either arginine which is more basic 
or glutamic acid which has a negative charge (LAM-KR and 
LAM-LE,  respectively), were prepared. Isoleucine position 
substituted analogs, in which the isoleucine residue in the 
LAM-L  was substituted with either leucine, norleucine, valine 
and alanine (LAM-IL,  -IX, -IV and -IA, respectively), were 
synthesized (Table 1). Homologs and different species laminin 
peptide segments containing the corresponding region of 
LAM-L  were prepared using mouse laminin ct2 chain, human 
laminin a3 chain and Drosophila laminin a chain sequences 
[25-27] (MER-12, KAL-12 and DOR-12, respectively). 
Cell attachment and neurite outgrowth activities of reverse- 
sequence and mirror image compounds of the IKVAV peptide 
(LAM-L)  were examined using rat pheochromocytoma PC12 
cells (Fig. 1A,B). Previously, the reverse-sequence of the Arg- 
Gly-Asp (RGD)  peptide from fibronectin was shown to inhibit 
cell adhesion on the cell binding domain of f ibronectin as well 
as the native RGD peptide [28]. The reverse-sequence laminin- 
derived peptide containing all-L- and all-D-amino acids (LAM- 
LR and LAM-DR,  respectively) did not showed cell attach- 
ment activities. The all-L- and all-D-peptides (LAM-L and 
LAM-D,  respectively), which were previously shown to pro- 
mote cell adhesion and tumor growth [20], showed cell attach- 
ment activity for PC12 cells as expected (Fig. 1A). LAM-D had 
reduced neurite outgrowth promot ion activity with approxi- 
mately 60% of the activity of that observed with the potent 
peptide (Fig. 1B). These results indicate that both all-L- and 
all-D-containing IKVAV peptides can bind to cell surface recep- 
tors or binding proteins, but that the all-L- and all-D-VAVKI- 
containing peptides (a reverse-sequence of IKVAV peptide) 
cannot interact. These results suggest that the structural re- 
quirements of IKVAV peptide for interaction with its cell sur- 
face receptor or binding proteins are specified by the specific 
primary structure. Cell attachment and neurite outgrowth pro- 
motion activities of laminin-1 were considerably higher than 
Table 1 
Synthetic peptides and their biological activities with PC12 cells 
Peptide Sequence Cell Neurite 
attachment outgrowth 
LAM-L AAS I KVAVSADR ++ ++ 
LAM-D AAS I KVAVSADR ++ + 
LAM-LR RDASVAVKI  SAA - N.D. 
LAM-DR RDASVAVKI  SAA - -  N.D. 
LAM-RM AASWIAKSADR - N.D. 
LAM-KR AAS IRVAVSADR ++ + 
LAM-KE AAS I~-VAVSADR - N.D. 
LAM-IL AASLKVAVSADR + - 
LAM-IX AASXKVAVSADR ++ + 
LAM-IV AASVKVAVSADR ++ - 
LAM- IA  AASAKVAVSADR - N.D. 
MER-12 ANS IKVSVGGGG ++ ++ 
KAL-12 AASKVAVPMRFN - N.D. 
DOR-12 ANS IKVGVNFKP ++ ++ 
LAM-L, all-L-configuration mouse laminin ctl chain peptide segment 
(residue 2,097 2,108 [24]); LAM-D, all-D-configuration LAM-L; 
LAM-LR, reverse-sequence LAM-L; LAM-DR, reverse-sequence 
LAM-D; LAM-RM, all-L-configuration laminin segment with the 
IKVAV segment scrambled; LAM-KR and -KE; the lysine in LAM-L 
is replaced with arginine or glutamic acid, respectively; LAM-IL, -IX, 
-IV and oIA; the isoleucine in LAM-L is replaced with leucine, norleuc- 
ine, valine and alanine, respectively. MER-12, mouse laminin or2 chain 
peptide segment (residue 2,137-2,148 [25]); KAL-12, human laminin ~3 
chain peptide segment (residue 763-774 [26]); DOR-12, Drosophila lam- 
inin a chain peptide segment (residue 2,5685,579 [27]). D-configuration 
amino acids are underlined. Replaced amino acids are written in bold 
type. All peptides have C-terminal amides. Cell attachment and neurite 
outgrowth activities (Figs. 1 and 2) are summarized: ++activity compa- 
rable to that of LAM-L; +active but weaker than LAM-L; - ,  no activ- 
ity; N.D., not determined. 
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Fig. 1. Attachment (A) and neurite outgrowth promotion (B) of PC12 cells on various ynthetic peptides and on laminin-1. Each value represents 
the mean of three separate determinations + S.E. Duplicate xperiments gave similar esults. Coating efficiencies oflaminin-I (5/lg/well) and the 
synthetic peptides (500,ug/well) were 43.8% (laminin-1), 1.9% (LAM-L), 1.4% (LAM-D), 3.4% (LAM-LR), 2.8% (LAM-DR) and 0.9% (LAM-RM). 
those of LAM-L on a molar basis. This is not surprising be- 
cause small peptides usually have less rigid conformations and 
laminin-1 can also interact with cell surface receptors through 
ancillary sites. 
Next we tested the importance of the lysine position in the 
IKVAV sequence for biological activities using single amino 
acid substituted analogs, in which the lysine was replaced with 
Arg or Glu (LAM-KR and LAM-KE, respectively). The argin- 
ine residue has the strongest basic charge among the amino 
acids and is present in the active sequences of many extracellu- 
lar matrix proteins [7,29]. In addition, arginine residues likely 
play an important role in interaction with integrins [29]. The 
arginine-containing IKVAV substituted peptide, LAM-KR, 
showed cell attachment comparable tothat of LAM-L, but the 
glutamic acid substituted peptide, LAM-KE, did not show ac- 
tivity (Fig. :2A). However, LAM-KR could not promote neurite 
outgrowth as well as that of the IKVAV peptide (LAM-L) 
showing about 60% of the activity (Fig. 2B). These results 
suggest that the contribution of the lysine residue of the 
IKVAV sequence is critical for biological activity. A positive 
charge in this location is important for cell attachment and is 
replaceable with other basic amino acids such as an arginine. 
The lysine residue is specifically required for a more complex 
biological function such as neurite outgrowth. 
The importance of the isoleucine residue of the IKVAV se- 
quence for biological activity was examined using several ana- 
logs in which the isoleucine was substituted with leucine (LAM- 
IL), norleucine (LAM-IX), valine (LAM-IV) and alanine 
(LAM-IA). LAM-IX and LAM-IV were as active for cell at- 
tachment as LAM-L. However, LAM-IL had weaker cell at- 
tachment activity than that of LAM-L and LAM-IA did not 
show this activity (Fig. 2C). Furthermore, LAM-IX showed 
approximately half of the activity for neurite outgrowth as 
LAM-L, and LAM-IL and LAM-IV did not promote neurite 
outgrowth (Fig. 2D). These results indicate that a bulky amino 
acid and/or fl-branched side chain is important in this position 
for biological function. 
Three synthetic peptides containing the corresponding re- 
gions of IKVAV in other laminin ~ chains including mouse 
laminin c~2 chain (MER-12) [25], human laminin ~3 chain 
(KAL-12) [26] and Drosophila laminin a chain (DOR-12) [27] 
were tested for PC12 cell adhesion and neurite outgrowth. 
MER-12 and DOR-12 showed cell attachment activity compa- 
rable to that of LAM-L, whereas, KAL- 12 was not active (Fig. 
2E). MER- 12 and DOR- 12 promoted neurite outgrowth as well 
as LAM-L (Fig. 2F). MER-12 and DOR-12 contain IKVSV 
and IKVGV sequences, respectively. However, in KAL-12 se- 
quence (SKVAV), the isoleucine which is a critical residue of 
the IKVAV sequence for biological activity, is absent. These 
results are in agreement with the above structure activity study 
using isoleucine-substituted analogs. The coating efficiency of 
the synthetic peptides are 1.9% (LAM-L), 3.4% (MER-12), 
0.5% (KAL-12) and 1.3% (DOR-12). Cell attachment and 
neurite outgrowth activities of the each peptide are similar 
values at 50 mg/well and 500 mg/well (Fig. 2E,F). These results 
indicate that differences in the peptide coating efficiencies does 
not significantly effect he comparison of the biological activi- 
ties of the peptides within these concentrations. 
In this paper, we have studied the effects of structural 
changes on the biological activity of the IKVAV containing 
12-mer peptide. The structural requirements of the IKVAV 
sequence for promotion of cell attachment and neurite out- 
growth were found to be very specific. The isoleucine and lysine 
residues are critical for biological functions but some differ- 
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Fig. 2. Attachment (A,C,E) and neurite outgrowth promotion (B, D, 
F) of PCI2 cells on various ynthetic peptides. Each value represents 
the mean of three separate determinations + S.E. Duplicate experi- 
ments gave similar esults. Coating efficiencies of the synthetic peptides 
(500 ,ug/well) were 1.9% (LAM-L), 7.0% (LAM-KR), 10.4% (LAM- 
KE), 0.7% (LAM-IL), 2.7% (LAM-IX), 1.4% (LAM-IV), 0.4% (LAM- 
IA), 3.4% (MER-12), 0.5% (KAL-12) and 1.3% (DOR-12). 
ences were noted in that some analogs could promote cell 
adhesion but had no effect on neurite outgrowth. These data 
suggest the possibility of more than one receptor on these cells 
for this domain, and that there may be different receptors 
depending on the cellular function. Changing the peptide struc- 
ture could aid in the characterization a d identification of spe- 
cific receptors or binding proteins for the IKVAV sequence. In 
addition, identification of these structure-activity requirements 
is useful for designing more potent agonistic or inhibitory com- 
pounds of the IKVAV peptide for therapeutics which could be 
used in nerve regeneration or angiogenesis studies. 
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